Medicus Pharma seeks orphan drug status

Medicus Pharma has submitted an application to the U.S. FDA for Orphan Drug Designation for its SkinJect® treatment for Gorlin Syndrome. This rare, high-burden genetic condition currently lacks approved therapies. The submission represents a significant step forward in developing a non-surgical treatment option for recurrent basal cell carcinoma associated with the syndrome.